Oncotype DX 2017 vs current OncotypeDX reporting

Options
beach2beach
beach2beach Member Posts: 996

Hi,

Is there a difference between an OncotypeDX done in 2017 vs now? If so, is there a way or place to input the information and see if percentages etc. change?

My recurrence score was a 9. 10yr risk of distance recurrence with 5yr of Tamox alone was 6% :Less than 2% benefit of Chemo benefit after 5yrs of Tamox... And absolute benefit of Chemo at 10 years by recurrence score was 0%.

Just curious.

Comments

  • Beesie
    Beesie Member Posts: 12,240
    edited March 2021

    Yes, for node negative there is a difference. The TAILORx study came out in late 2018 and the Oncotype node neg. recurrence risk estimates for low to intermediate scores were adjusted to reflect the new findings.

    As far as I know there is nowhere that you can input your score to have it recalculate. I do however have the results from the TAILORx study. The following chart is found in the Supplementary Appendix. https://www.nejm.org/doi/full/10.1056/NEJMoa1804710


    • The top graph is for those aged 50 and under; the bottom graph is for over age 50.
    • The red and blue solid lines reflect the 9-year metastatic recurrence risk estimates that are now associated with each Oncotype score.
    • The solid red line reflects endocrine therapy only (either Tamoxifen or an AI) . The red line stops at a 25 score because everyone in the study with a higher score was given chemo (or they were kicked out of the study).
    • The solid blue line reflects chemo + endocrine therapy. The blue line only starts at an 11 Oncotype score because no chemo was given to those with lower scores.
    • The red and blue dotted lines on the chart are the high and low ranges - the solid line is the average.

    image

  • beach2beach
    beach2beach Member Posts: 996
    edited March 2021

    As always Beesie, you are a wealth of information and know how to relay it to us in terms we can understand.

    Thanks!!

Categories